ReviewKorean journal of urology2013
Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects.
Review in Korean journal of urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- A systematic review of neurocognitive dysfunction with overactive bladder medications.International urogynecology journal · 2021Pooled it
- Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.International urology and nephrology · 2019Trial
- From dopamine to muscarine: xanomeline-trospium (KarXT) as a novel direction in the psychopharmacotherapy of schizophrenia.Frontiers in pharmacology · 2026Review
- Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.BMJ medicine · 2024Article
- Safety and Tolerability of Fesoterodine in Older Adult Patients with Overactive Bladder.Canadian geriatrics journal : CGJ · 2022Review
- Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia.Drugs & aging · 2021Article
- Anticholinergic drugs and risk of dementia: Time for action?Pharmacology research & perspectives · 2021Article
- Alzheimer's disease and related dementias risk: Comparing users of non-selective and M3-selective bladder antimuscarinic drugs.Pharmacoepidemiology and drug safety · 2020Article
- Efficacy and safety of non-ablative vaginal erbium:YAG laser treatment as a novel surgical treatment for overactive bladder syndrome: comparison with anticholinergics and β3-adrenoceptor agonists.World journal of urology · 2019Article
- Dealing with complex overactive bladder syndrome patient profiles with focus on fesoterodine: in or out of the EAU guidelines?Research and reports in urology · 2017Review
- A Chinese Medicine Formula "Xian-Jia-Tang" for Treating Bladder Outlet Obstruction by Improving Urodynamics and Inhibiting Oxidative Stress through Potassium Channels.Evidence-based complementary and alternative medicine : eCAM · 2017Article
- Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence.International urogynecology journal · 2016Article
- An overlooked effect of systemic anticholinergics: alteration on accommodation amplitude.International journal of ophthalmology · 2016Article
- Associations of carotid artery plaque with lower urinary tract symptoms and erectile dysfunction.International urology and nephrology · 2014Article
- Overactive bladder in the vulnerable elderly.Research and reports in urology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCentral nervous system (CNS) and cardiovascular system (CVS) side effects of anticholinergic agents used to treat overactive bladder (OAB) are underreported. Hence, this review aimed to focus on the mechanisms of CNS and CVS side effects of anticholinergic drugs used in OAB treatment, which may help urologists in planning the rationale for OAB treatment. MATERIALS AND
methodsPubMed/MEDLINE was searched for the key words "OAB," "anticholinergics," "muscarinic receptor selectivity," "blood-brain barrier," "CNS," and "CVS side effects." Additional relevant literature was determined by examining the reference lists of articles identified through the search.
resultsCNS and CVS side effects, pharmacodynamic and pharmacokinetic properties, the metabolism of these drugs, and the clinical implications for their use in OAB are presented and discussed in this review.
conclusionsTrospium, 5-hydroxymethyl tolterodine, darifenacin, and solifenacin seem to have favorable pharmacodynamic and pharmacokinetic properties with regard to CNS side effects, whereas the pharmacodynamic features of darifenacin, solifenacin, and oxybutynin appear to have an advantage over the other anticholinergic agents (tolterodine, fesoterodine, propiverine, and trospium) with regard to CVS side effects. To determine the real-life situation, head-to-head studies focusing especially on CNS and CVS side effects of OAB anticholinergic agents are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.